HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8835501, which covers Beleodaq™ (belinostat) for Injection on September 16, 2014 with patent term adjustment from May 2026 to October 2027. In addition to the existing patent, covering the chemical entity of Beleodaq, this new patent covers the formulation of the product, strengthening and expanding significantly its industrial property protection.
Help employers find you! Check out all the jobs and post your resume.
